The effect of islet-activating protein (IAP) purified from culture medium of Bordetella pertussis was examined in dogs. This was assessed by the levels of pancreatic polypeptide (PP) as well as the responses of plasma insulin and glucagon to a parasympathomimetic agent, bethanechol. Plasma responses of these pancreatic hormones were measured before and 5 days after IAP injection.
Islet-activating protein (IAP), purified from culture medium of Bordetella pertussis, has an enhancing effect on the insulin secretory response to various stimulants both in vitro (Katada and Ui, 1979; Katada and Ui, 1981) and in vivo (Toyota et al., 1978; Yoshida et al., 1981) . A single injection of IAP into spontaneously diabetic rats or alloxan-treated dogs normalized glucose tolerance. This effect of result, at least partly, from an increase in insulin secretion (Toyota et al., 1978 ; Yoshida et al., 1981) . On the other hand, glucagon secretion in response to norepinephrine was reduced after IAP treatment in both the diabetic and the normal rats (Toyota et al., 1978) . In alloxan-treated doges the glucagon response to arginine or glucose was significantly lowered by IAP when compared with a saline control (Yoshida et al., 1981) .
Because IAP has opposite effects on pancreatic A-and Bcells, it is of interest to know whether IAP has stimulative or inhibitory effects on the other pancreatic endocrine cells, namely the D-and PP-cells. However, no reports exist regarding the influence of IAP on secretions of somatostation and pancreatic polypeptide (PP) from the pancreatic islets.
The purpose of this paper is to clarify the effect of IAP on PP secretion. We used bethanechol as a stimulant of PP. Bethanechol is known not only to stimulate insulin secretion (Kaneto et al., 1969) , but also is postulated to stimulate the release of glucagon and PP, since the secretion of glucagon and PP was shown to be markedly increased by parasympathomimetic agents such as acetylcholine (Kaneto and Kosaka, 1974 ; Adrian et al., 1978) . In this report we compared the bethanecholstimulated PP response before and after IAP treatment. et al.
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Japon The concentration of plasma immunoreactive glucagon (IRG) was measured by radioimmunoassay using the antiserum (30K) specific for pancreatic glucagon as previously described (Nonaka and Foa, 1968 plasma glucose, IRI, IRG and PP to bethanechol before and five days after the injection of IAP. The mean plasma glucose level after IAP treatment tended to become lower than that before IAP injection, although the difference between them was not statistically significant.
Plasma IRI and IRG levels after IAP treatment were almost the same as those before IAP injection. On the other hand, bethanecholstimulated release of PP after IAP treatment was lower than that before IAP; a statistically significant difference was observed at 20 min after bethanechol injection (p<0.05). IAP had no effect on the incremental area of IRI (Figure 2, left panel) . Although the incremental area of IRG after IAP injection tended to be smaller than that before IAP injection, the difference between them was not statistically significant (Figure 2, middle panel) . On the other hand, incremental area of PP after IAP injection was significantly smaller than that before IAP injection (p<0.05, Figure  2 , right panel).
Discussion
The present investigation demonstrated an inhibitory effect of IAP on bethanecholstimulated PP release. This is the first report that revealed the effect of IAP on PP secretion.
The mechanism by which IAP reduces PP response to bethanechol is not clear. Cholinergic agents such as bethanechol are related to the increase in the tissue content and plasma concentration of cyclic guanosine 3', 5'-monophosphate (cyclic GMP) (Honma and Ui, 1978) . Although the influence of IAP on cyclic GMP has not yet been clearly known, a preliminary study showed that the inhibitory effect of IAP on acetylcholine-induced increases in the plasma concentration of cyclic GMP (personal communication from Dr. Ui, Hokkaido University). Taking these data into consideration, it may be hypothesized that the suppressive effect of IAP on bethanechol stimulated PP secretion is mediated through the inhibition of cyclic GMP level.
But the precise machanism for the influence of TAP on PP secretion remains to be elucidated.
Although IAP was reported to stimulate insulin response to various secretagogues (Yajima et al., 1978 a; b) , IAP did not augment insulin release in our experiment. We consider that the discrepancy between our results and the previous reports about the influence of IAP on insulin response might be due to the difference in stimulants.
Although several reports (Katada and Ui, 1979 a; b) revealed that the stimulative effect of IAP on insulin secretion was mediated through the activation of Cachannel and the resultant increase in cyclic adenosine 3' 5'-monophosphate (cyclic AMP), the mechanism for the bethanecholstimulated insulin release has not been shown to be related to the increase in cyclic AMP. Since insulin secretion is not mediated through cyclic GMP, which may be related to the reduction of PP response to bethanechol after IAP treatment, as mentioned before, it is possible that insulin response to bethanechol is not affected by With regard to the effect of IAP on glucagon secretion, some disagreement has been noted. Toyota et al. (1978) reported that glucagon secretion in response to norepinephrine was reduced after IAP treatment in both the diabetic and the normal rats. On the other hand, Yoshida et al., (1981) showed that the suppressive effect of IAP on glucagon response to arginie or glucose was seen only in alloxantreated dogs but not in normal dogs. They proposed that improvement in insulin deficiency might have reduced the glucagon response to arginine or glucose in alloxan treated dogs. In the present study glucagon response to bethanechol tended to decrease after IAP treatment, although the difference was not statistically significant. This result does not fully accord either with reports by Toyota et al, or by Yoshida et al. 
